Your browser doesn't support javascript.
loading
Structure-Activity Relationship of Oxacyclo- and Triazolo-Containing Respiratory Syncytial Virus Polymerase Inhibitors.
Tran, Minh T; Grosse, Sandrine; Carbajo, Rodrigo J; Jacoby, Edgar; Yin, Yanting; Yu, Xiaodi; Martinez, Carol; Stoops, Bart; Cooymans, Ludwig; Hu, Lili; Lutter, Ferdinand H; Pieters, Serge; Tan, Eric; Alcázar, Jesus; Roymans, Dirk; van Vlijmen, Herman; Rigaux, Peter; Sharma, Sujata; Jonckers, Tim H M.
Afiliação
  • Tran MT; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
  • Grosse S; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
  • Carbajo RJ; Janssen Research and Development, Janssen-Cilag, S.A., C/Jarama 75, 45007 Toledo, Spain.
  • Jacoby E; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
  • Yin Y; Johnson & Johnson Innovative Medicine, Spring House, Pennsylvania, Pennsylvania 19477, United States.
  • Yu X; Johnson & Johnson Innovative Medicine, Spring House, Pennsylvania, Pennsylvania 19477, United States.
  • Martinez C; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
  • Stoops B; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
  • Cooymans L; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
  • Hu L; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
  • Lutter FH; Chemical Process R&D, Discovery Process Research, Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
  • Pieters S; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
  • Tan E; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
  • Alcázar J; Janssen Research and Development, Janssen-Cilag, S.A., C/Jarama 75, 45007 Toledo, Spain.
  • Roymans D; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
  • van Vlijmen H; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
  • Rigaux P; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
  • Sharma S; Johnson & Johnson Innovative Medicine, Spring House, Pennsylvania, Pennsylvania 19477, United States.
  • Jonckers THM; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
ACS Med Chem Lett ; 15(9): 1549-1558, 2024 Sep 12.
Article em En | MEDLINE | ID: mdl-39291020
ABSTRACT
Despite the availability of medicines preventing respiratory syncytial virus (RSV) infection, post-exposure treatment options are needed for addressing patient's needs. RSV non-nucleoside polymerase inhibitors (NNI) have emerged as a promising asset for which our group previously disclosed JNJ-8003 with potent in vitro antiviral activity and pronounced in vivo efficacy. In this work, a structural-guided design to modify the linker vector of JNJ-8003 resulted in the identification of 2-oxacyclo pyridine-containing derivatives whose various ring closing strategies are described. In addition, bioisosteric replacement of an amide bond with triazole retained potency, and cryo-electron microscopy (cryo-EM) confirmed binding in the capping domain. Subsequent NMR conformational analysis suggested a correlation between the potency and conformations. Our efforts have fulfilled the aim of identifying linker modifications with maintained biological activity while enriching structural diversity and allowing modulations of other parameters.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: ACS Med Chem Lett Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Bélgica

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: ACS Med Chem Lett Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Bélgica